ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015
(Thomson Reuters ONE) -
REGULATED INFORMATION
* Caplacizumab on track to enter Phase III in acquired TTP, with Ablynx
committed to lead commercialisation in Europe and the USA
* 4 Phase II clinical programmes progressing in RSV, RA and SLE
* Significant expansion of immuno-oncology deal with Merck & Co., Inc. now up
to 17 programmes
* New partnerships established with Genzyme and Taisho
* Revenue and grant income up 73% to ?38.4 million
* Successful issue of ?100 million convertible bond, with ?268.4 million in
cash at 30 June 2015
Webcast presentation scheduled today at 4 pm CET (10 am EST); accessible by
clicking here or on the Ablynx website at http://www.ablynx.com/news/events-
presentations/
To participate in the Q&A, dial +32(0)2 402 30 92 with confirmation code 6867520
GHENT, Belgium, 27 August 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced its business update and results for the six-month period ending
30 June 2015, which have been prepared in accordance with the IAS 34 "Interim
Financial Reporting" as adopted by the European Union.
Dr Edwin Moses, CEO of Ablynx commented:
"We have made substantial progress on all fronts, in our own fully-owned
programmes and in our partnerships with leading pharmaceutical companies. In our
later stage clinical pipeline we are now running four Phase II studies and will
be shortly commencing the Phase III study with our wholly-owned anti-vWF
Nanobody®, caplacizumab, as a potential first-in-class treatment for the orphan
blood disease acquired TTP. We intend to apply for conditional approval of this
product in Europe at the beginning of 2017 and, following a review of the
commercialisation options, we have concluded that this product represents a
strategic opportunity in our evolution into a commercial stage company and the
value is best maximised by Ablynx retaining 100% ownership of the product in the
USA and Europe."
"We significantly expanded our presence in immuno-oncology with an extension of
our collaboration with Merck & Co., Inc. in a deal which now includes up to 17
programmes and could generate up to ?5.7 billion in milestones plus royalties.
We anticipate increasing our staff by about 10% to 350 during 2015 to resource
this important partnership and the other opportunities we are pursuing."
"Thanks to an oversubscribed convertible bond issue of ?100 million, we have
substantially expanded our stakeholder base and are now well funded to execute
on our potential as we look forward to multiple key inflection points, including
the release of data from our Phase IIa study with ALX-0171 in infants with RSV
planned for H1 2016, the results from the Phase IIb studies with ALX-0061 in RA
planned for H2 2016, and the potential launch of caplacizumab in 2018."
Key figures (in ? million)
+--------------------------------+--------------+-------------+----------+
| | H1 2015 | H1 2014 | Variance |
+--------------------------------+--------------+-------------+----------+
| Total revenue and grant income | 38.4 | 22.2 | 73% |
+--------------------------------+--------------+-------------+----------+
| R&D income | 38.0 | 21.8 | 74% |
+--------------------------------+--------------+-------------+----------+
| Grants | 0.4 | 0.4 | 0% |
+--------------------------------+--------------+-------------+----------+
| Operating expenses | (45.9) | (29.8) | 54% |
+--------------------------------+--------------+-------------+----------+
| R&D | (40.3) | (24.5) | 64% |
+--------------------------------+--------------+-------------+----------+
| G&A | (5.6) | (5.3) | 6% |
+--------------------------------+--------------+-------------+----------+
| Operating result | (7.4) | (7.6) | 3% |
+--------------------------------+--------------+-------------+----------+
| Net financial result | (7.7) | 1.3 | (692%) |
+--------------------------------+--------------+-------------+----------+
| Net result | (15.2) | (6.3) | 141% |
+--------------------------------+--------------+-------------+----------+
| Net cash burn | (35.0) ((1)) | (4.4) | (695%) |
+--------------------------------+--------------+-------------+----------+
| Cash at 30 June* | 268.4 ((2)) | 196.0 ((3)) | 37% |
+--------------------------------+--------------+-------------+----------+
((1) )Excluding net proceeds of ?97.2M from the convertible bonds, which
raised ?100 million, announced on 20 May 2015
((2) )Including ?1.6 million in restricted cash and net proceeds from the
convertible bonds
((3) )Including ?2.0 million in restricted cash
* Defined as liquidity position in the cash flow statement
The complete version of this press release is available via the link at the
bottom of this page.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new medicines
which will make a real difference to society. Today, the Company has more than
30 proprietary and partnered programmes in development in various therapeutic
areas including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple pharmaceutical
companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck &
Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx(at)instinctif.com
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx(at)instinctif.com
pdf format of the press release:
http://hugin.info/137912/R/1947723/707281.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1947723]
Unternehmensinformation / Kurzprofil:
Datum: 27.08.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 416187
Anzahl Zeichen: 8135
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
